Characteristics of patients with POEMS syndrome undergoing autoHCT
| Characteristic . | N = 331 (%) . |
|---|---|
| Median age (range), median (min-max) | 51 (18-77) |
| Sex | |
| Male (%) | 220 (66) |
| Female (%) | 111 (34) |
| Race, no. (%) | |
| White | 215 (65) |
| Black or African American | 64 (19) |
| Asian | 17 (5) |
| Native Hawaiian or other Pacific Islander | 1 (0) |
| American Indian or Alaska Native | 1 (0) |
| Missing | 33 (10) |
| Region, no. (%) | |
| United States | 303 (92) |
| Canada | 10 (3) |
| Asia | 9 (3) |
| Australia/New Zealand | 3 (1) |
| Middle East/Africa | 1 (0) |
| Central/South America | 5 (2) |
| Karnofsky score, no. (%) | |
| ≥90 | 89 (27) |
| <90 | 233 (70) |
| Missing | 9 (3) |
| HCT-CI, no. (%) | |
| 0 | 81 (24) |
| 1 | 38 (11) |
| 2 | 43 (13) |
| 3 | 81 (24) |
| 4 | 41 (12) |
| 5 | 22 (7) |
| 6+ | 21 (7) |
| Missing | 4 (1) |
| Creatinine, mg/dL; no. (%) | |
| mgdL | 319 (96) |
| mgdL | 7 (2) |
| Missing | 5 (2) |
| Melphalan dose(mg/m), no. (%) | |
| MEL 140 | 42 (13) |
| MEL 200 | 289 (87) |
| Organ comorbidity based on HCT-CI: cerebrovascular, no. (%) | 18 (5) |
| Organ involvement based on HCT-CI: hepatic, no. (%) | 10 (3) |
| Organ involvement based on HCT-CI: pulmonary, no. (%) | 172 (52) |
| Mobilization, no. (%) | |
| G-CSF + plerixafor | 94 (28) |
| G-CSF | 72 (22) |
| G-CSF + chemotherapy | 29 (9) |
| G-CSF + plerixafor + chemotherapy | 5 (2) |
| Chemotherapy | 2 (1) |
| Unknown | 129 (39) |
| Disease status prior to transplant, no. (%) | |
| sCR/CR | 23 (7) |
| VGPR | 22 (7) |
| PR | 79 (24) |
| SD | 87 (26) |
| PD/relapse | 19 (6) |
| Never treated | 72 (22) |
| Missing | 29 (8) |
| Time from diagnosis to HCT, no. (%) | |
| mo | 132 (40) |
| 6-12 mo | 112 (34) |
| 12-24 mo | 44 (13) |
| mo | 42 (13) |
| Missing | 1 (0) |
| Year of transplant, no. (%) | |
| 2008 | 15 (5) |
| 2009 | 14 (4) |
| 2010 | 19 (6) |
| 2011 | 25 (8) |
| 2012 | 27 (8) |
| 2013 | 37 (11) |
| 2014 | 35 (11) |
| 2015 | 41 (12) |
| 2016 | 50 (15) |
| 2017 | 32 (10) |
| 2018 | 36 (11) |
| Follow-up median (range) | 48 (3-137) |
| Characteristic . | N = 331 (%) . |
|---|---|
| Median age (range), median (min-max) | 51 (18-77) |
| Sex | |
| Male (%) | 220 (66) |
| Female (%) | 111 (34) |
| Race, no. (%) | |
| White | 215 (65) |
| Black or African American | 64 (19) |
| Asian | 17 (5) |
| Native Hawaiian or other Pacific Islander | 1 (0) |
| American Indian or Alaska Native | 1 (0) |
| Missing | 33 (10) |
| Region, no. (%) | |
| United States | 303 (92) |
| Canada | 10 (3) |
| Asia | 9 (3) |
| Australia/New Zealand | 3 (1) |
| Middle East/Africa | 1 (0) |
| Central/South America | 5 (2) |
| Karnofsky score, no. (%) | |
| ≥90 | 89 (27) |
| <90 | 233 (70) |
| Missing | 9 (3) |
| HCT-CI, no. (%) | |
| 0 | 81 (24) |
| 1 | 38 (11) |
| 2 | 43 (13) |
| 3 | 81 (24) |
| 4 | 41 (12) |
| 5 | 22 (7) |
| 6+ | 21 (7) |
| Missing | 4 (1) |
| Creatinine, mg/dL; no. (%) | |
| mgdL | 319 (96) |
| mgdL | 7 (2) |
| Missing | 5 (2) |
| Melphalan dose(mg/m), no. (%) | |
| MEL 140 | 42 (13) |
| MEL 200 | 289 (87) |
| Organ comorbidity based on HCT-CI: cerebrovascular, no. (%) | 18 (5) |
| Organ involvement based on HCT-CI: hepatic, no. (%) | 10 (3) |
| Organ involvement based on HCT-CI: pulmonary, no. (%) | 172 (52) |
| Mobilization, no. (%) | |
| G-CSF + plerixafor | 94 (28) |
| G-CSF | 72 (22) |
| G-CSF + chemotherapy | 29 (9) |
| G-CSF + plerixafor + chemotherapy | 5 (2) |
| Chemotherapy | 2 (1) |
| Unknown | 129 (39) |
| Disease status prior to transplant, no. (%) | |
| sCR/CR | 23 (7) |
| VGPR | 22 (7) |
| PR | 79 (24) |
| SD | 87 (26) |
| PD/relapse | 19 (6) |
| Never treated | 72 (22) |
| Missing | 29 (8) |
| Time from diagnosis to HCT, no. (%) | |
| mo | 132 (40) |
| 6-12 mo | 112 (34) |
| 12-24 mo | 44 (13) |
| mo | 42 (13) |
| Missing | 1 (0) |
| Year of transplant, no. (%) | |
| 2008 | 15 (5) |
| 2009 | 14 (4) |
| 2010 | 19 (6) |
| 2011 | 25 (8) |
| 2012 | 27 (8) |
| 2013 | 37 (11) |
| 2014 | 35 (11) |
| 2015 | 41 (12) |
| 2016 | 50 (15) |
| 2017 | 32 (10) |
| 2018 | 36 (11) |
| Follow-up median (range) | 48 (3-137) |